

Determination of Colistin and Tigecycline Resistance Profile of *Acinetobacter Baumannii* Strains from Different Clinical Samples in a Territory Hospital in Turkey

Merih Şimşek, Ph.D., Cengiz Demir, M.Sc.

Department of Medical Microbiology, School of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, 03030, Turkey.

Received 1 July 2019 • Revised 10 December 2019 • Accepted 28 January 2020 • Published online 26 February 2020

Abstract:

Objective: *Acinetobacter baumannii* (*A. baumannii*) can develop resistance to various antimicrobial agents via different mechanisms. Hence, the aim of this study was to investigate, by using different methods, the resistance profiles of *A. baumannii* strains isolated from different clinical specimens; from colistin and tigecycline antibiotics, and also the distribution of this resistance according to the clinical samples.

Material and Methods: For this study, 1,265 clinical samples (a samples from each patient) were obtained from various clinics, between; January 2015/December 2018. Identification was conducted by VITEK® 2 compact (bioMerieux, USA) and conventional biochemical tests. Antibiotic susceptibility tests were performed by VITEK 2, and the results of colistin and tigecycline were confirmed by E test and the broth microdilution method.

Results: *A. baumannii* strains (1,265) were most frequently isolated from tracheal aspirate, sputum and blood samples. At the same time, strains were obtained from intensive care units (70.4%) as well as other clinics (29.6%). The rates of colistin and tigecycline-resistant strains were determined using VITEK 2, E test and the broth microdilution methods as: 3.0%, 5.7%, 9.0% and 21.7%, 24.5%, 33.0%, respectively.

Conclusion: The determination of appropriate antibiotics are important for empirical treatment. Colistin and tigecycline have become prominent as an important, alternative agent in the treatment of *A. baumannii*-related infections. The results of this study show that colistin and tigecycline resistance rates in intensive care units have been increasing gradually over the years. Monitoring of resistance patterns of nonfermentative bacteria, isolated from intensive care units, is important for the immediate initiation of appropriate empirical treatment. In-vitro studies with *A. baumannii* strains should also be supported by clinical trials.

Keywords: *Acinetobacter baumannii*, broth microdilution, colistin, tigecycline

Contact: Asst. Prof. Merih Şimşek, Ph.D.
Department of Medical Microbiology, School of Medicine,
Afyonkarahisar Health Sciences University, Afyonkarahisar, 03030, Turkey.
E-mail: smerih16@gmail.com

J Health Sci Med Res 2020;38(2):81-91
doi: 10.31584/jhsmr.2020727
www.jhsmr.org

© 2020 JHSMR. Hosting by Prince of Songkla University. All rights reserved.
This is an open access article under the CC BY-NC-ND license
(<http://www.jhsmr.org/index.php/jhsmr/about/editorialPolicies#openAccessPolicy>).

Introduction

Acinetobacter baumannii (*A. baumannii*) is gram negative bacterium, which is mostly isolated from intensive care units. It has high clinical important in the world, and in our country, due to the continuous increase in multidrug-resistant *A. baumannii*.^{1,2}

Colistin and tigecycline have become prominent as an important alternative agent used especially for the treatment of infections related to carbapenems resistant *A. baumannii* strains.³⁻⁵ *A. baumannii* developed resistance to tigecycline has widely been used for many years^{6,7}; however, colistin is promising for the treatment of multidrug-resistant gram-negative bacteria. Although, the possibility of developing resistance to colistin is lower than carbapenems, it has also been reported that resistance to this agent may increase within some regions of the world over the coming years.^{8,9}

The follow up of colistin and tigecycline susceptibility profiles are important for world health all over. The aim of this study was to investigate, by using different methods, the resistance profiles of *A. baumannii* strains isolated from different clinical specimens from colistin and tigecycline antibiotics in addition to the distribution of this resistance according to clinical samples.

Material and Methods

Identification and isolation of bacterial

Culture and antibiotic susceptibility results of 1,265 clinical samples, (a samples from each patient) obtained from various clinics of Afyonkarahisar Health Sciences University, between; January 2015/December 2018; according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST) were evaluated. (According to the information provided by the clinicians, samples of the patients with infections were selected)

Bactec-Alert 3D (Becton Dickinson, Sparks, The United State of America) blood culture incubation system was used for the isolation of bacteria from the blood

cultures. Samples from the blood culture flasks giving positive signals were cultured on 5.0% sheep blood agar, and eosin methylene blue agar medium. Pediatric blood culture samples were also cultured on chocolate agar. The medium was then incubated at 37 °C for 24–48 hours. Urine samples were cultured quantitatively on blood agar and chromogen agar medium. The media were incubated at 37 °C for 18–24 hours. A colony count of 100,000 Colony Forming Unit/milliliter (ml) was considered significant for urine samples. All other clinical samples were cultured on 5.0% sheep blood, Eosin metilen blue agar and chocolate agar, then incubated at 37 °C for 24–48 hours. Bacteria isolated from these cultures were previously identified by VITEK 2 and conventional biochemical tests (Gram stain, oxidase test, fermentation property). These obtained isolates were stored in Tryptic Soy Broth (Oxoid-England) glycerin at -20 °C until being used for this study.

Antimicrobial susceptibility testing

Antibiotic susceptibility tests were performed by VITEK 2, whilst results of colistin and tigecycline were confirmed by E test and broth microdilution (BMD) method alone. *A. baumannii* isolates that were resistant to more than three of the existing antibiotics determined were identified as multi drug resistance (MDRs). However, pan drug resistance (PDRs) were defined as resistant to all available antibiotics. Extreme drug resistance (XDRs) were defined as resistant to all antibiotics; with the exceptions of colistin, tigecycline or one or two antibiotics.¹⁰ Antibiotics used for this purpose were determined as: gentamicin, amikacin, tobramycin, imipenem, meropenem, cefepime, ceftazidime, ampicillin-sulbactam, piperacillin, piperacillin-tazobactam, ciprofloxacin, levofloxacin, trimetoprim-sulfametoksazole, netilmicin, tigecycline and colistin. These antibiotics were determined according to EUCAST recommendations.¹¹ For VITEK 2 system external (One-world Ocuracy Company, Turkey), internal (*E. coli* American

Type Culture Collection (ATCC) 25922, *E. faecalis* ATCC 29212 and *S. aureus* ATCC 29213 strains were used) quality control studies were performed regularly, so as to check the accuracy of the work. The results of antibiotic susceptibility from VITEK 2 were evaluated according to EUCAST recommendations.¹¹

The BMD method; the bacterial suspensions were adjusted according to EUCAST recommendations for the BMD method. As described in EUCAST, *P. Aeruginosa*; ATCC 27853 were used for quality control of the BMD test. The microplates were incubated at 35 °C for 20 hours, then visually evaluated.

For the E test method; the 0.5 McFarland turbidity suspension of *A. baumannii* strains were prepared, and strains were cultured on a Muller hinton agar surface. After the plates were dried, colistin and tigecycline strips (AB Biodisk, Sweden) were placed. The plates were incubated at 35 °C for 24 hours. minimum inhibitory concentration (MIC) is defined as the lowest concentration of antibiotic capable of inhibiting the growth of the micro-organism. Therefore, the concentrations required to inhibit 50.0% and 90.0% of the strains (MIC 50 and MIC 90, respectively) were calculated for colistin and tigecycline.

MIC breakpoints

Colistin sensitivity breakpoint for *Acinetobacter*, the MIC breakpoint of ≤ 2 mg/L, is interpreted to be sensitive by EUCAST.¹¹ There are no MIC breakpoint values approved by EUCAST for tigecycline. For this reason, MIC breakpoints recommended for *Enterobacteriaceae* by the United States Food and Drug Administration (USFDA) (≤ 2 µg/ml susceptibility, ≥ 8 µg/ml resistance) were interpreted, and then based on these.^{11,12}

Ethical approval

Ethical approval for this retrospective study was obtained from the local ethics committee of Afyonkarahisar Health Sciences University.

Statistical analysis

Data obtained were entered and analysed in Microsoft Excel 2010. Statistical analysis was performed using the IBM Statistical Package for the Social Science (SPSS) Statistics 20. The results were analyzed by using chi-square method, with p -value <0.05 being accepted as statistically significant.

Results

Firstly, the distribution of 1,265 *A. baumannii* strains, according to samples included in this study, were analyzed. During this time, the distribution of *A. baumannii* strains were also determined according to the clinics. The percentages of observed strains, isolated from the different units were: intensive care unit (17.7%), anesthesia intensive care unit (15.5%) and neonatal intensive care unit (12.6%), respectively. However, *A. baumannii* strains were also isolated from; neurosurgery (5.8%), orthopedics and traumatology (3.9%) and general surgical (3.0%) clinics, respectively (Table 1). *A. baumannii* strains were most often isolated from tracheal aspirate, sputum and blood samples (Figure 1). The resistance of *A. baumannii* isolates to colistin and tigecycline were examined by comparing the intensive care unit to other clinics (Figure 2). The rates of colistin and tigecycline resistant strains were determined by using VITEK 2, E test and BMD as; 3.0%, 5.7%, 9.0% and 21.7%, 24.5% and 33.0%, respectively. In addition, a comparison was made of the interpretative results, MIC 50 and MIC 90 for colistin/tigecycline as well as susceptibility testing methods (Table 2). At the same time, resistance rates for other antibiotics used in the treatment of *A. baumannii* - related infections was found to be quite high. According to the antibiotic resistance profile, especially; ceftazidime (95.3%), cefepime (95.6%), ampicillin-sulbactam (94.5%), piperacillin (99.6%), piperacillin-tazobactam (98.9%), imipenem (95.3%), meropenem (96.1%), ciprofloxacin (94.3%) and levofloxacin (95.5%), are very noticeable with high resistance rates.

(Table 3) According to VITEK® 2 compact (bioMerieux, USA) and BMD results, all 1,265 *A. baumannii* isolates were determined as MDR with 9.0% as PDR and XDR. When the resistance rates of *A. baumannii* strains to colistin and tigecycline were examined by years, it was observed that the rates gradually increased (Table 4).

Table 1 Distribution according to clinics of *Acinetobacter baumannii* isolates

Clinics	Number of investigated strains (n)	Rate of investigated strains (%)
Intensive care units		
n (%) 891 (70.4)		
Chest Diseases Intensive Care	224	17.7
Anesthesia Intensive Care	197	15.5
Neonatal Intensive Care	160	12.6
Neurosurgery Intensive Care	108	8.5
Neurology Intensive Care	78	6.2
General Surgical Intensive Care	51	4.0
Internal Intensive Care	44	3.5
Coronary Intensive Care	21	1.7
Pediatric Intensive Care	8	0.6
Other clinics		
n (%) 374 (29.6)		
Neurosurgery	74	5.8
Orthopedics and Traumatology	50	3.9
General Surgical	38	3.0
Chest Diseases	37	2.9
Nephrology	31	2.5
Physical Therapy and Rehabilitation	24	1.9
Medical Oncology	20	1.6
Anesthesia	18	1.4
Neurology	15	1.2
Infectious Diseases	13	1.0
Internal Medicine	13	1.0
Pediatric Health and Diseases	11	0.9
Hematology	6	0.5
Other	24	1.9
Total	1,265	100.0




Figure 1 Distribution according to clinical sample types of *Acinetobacter baumannii* isolated (n/%)




Figure 2 Distribution according to clinical types and resistant number of *Acinetobacter baumannii* isolated (n)

Table 2 Comparison of interpretative results, and minimum inhibitory concentration 50 and minimum inhibitory concentration 90 for colistin/tigecycline, and susceptibility testing methods

Antibiotics and methods	n (%) of colistin/tigecycline-resistant/susceptible		MIC (µg/ml)	
	<i>A. baumannii</i>		50	90
	Resistant	Susceptible		
Colistin				
BMD	110 (9.0)	1,155 (91.0)	1.00	2.00
E test	72 (5.7)	1,193 (94.3)	0.50	0.75
VITEK 2	38 (3.0)	1,227 (97.0)	0.25	0.50
Tigecycline				
BMD	417 (33.0)	848 (67.0)	4.00	8.00
E test	311 (24.5)	954 (75.5)	1.50	4.00
VITEK 2	275 (21.7)	990 (78.3)	1.00	4.00

MIC=minimum inhibitory concentration, BMD=broth microdilution, µg/ml=microgram/milliliter

Table 3 The antibiotics resistance rates of *Acinetobacter baumannii* strains (n=1265)

Antibiotics	Number of resistant strains (n)	Resistance rates (%)
Tigecycline	275	21.7
Colistin	38	3.0
Amikacin	705	55.7
Gentamicin	846	66.9
Tobramycin	601	47.5
Ceftazidime	1,206	95.3
Cefepime	1,210	95.6
Ampicillin-sulbactam	1,195	94.5
Piperacillin	1,260	99.6
Piperacillin-tazobactam	1,251	98.9
Imipenem	1,206	95.3
Meropenem	1,216	96.1
Ciprofloxacin	1,193	94.3
Levofloxacin	1,205	95.5
Trimethoprim-sulfamethoxazole	872	68.9
Netilmicin	548	43.3

Table 4 The rates of resistance to colistin and tigecycline of *Acinetobacter baumannii* strains, according to years

Years (n)	Colistin Number (%)	Tigecycline Number (%)
2015 (136)	8 (5.8)	30 (22.0)
2016 (267)	18 (6.7)	72 (26.9)
2017 (407)	33 (8.1)	142 (34.8)
2018 (457)	51 (11.1)	173 (37.8)
Total (1265)	110*	417*

*Based on broth microdilution method results

In accordance with the data of our study, there was no statistically significant differences between the intensive care unit and other clinics, in terms of resistance of *A. baumannii* to colistin (p-value=0.061). However, there was a statistically significant difference between the intensive care and other clinics, in terms of the resistance of *A. baumannii* to tigecycline (p-value=0.001). In addition, colistin and tigecycline resistance of *A. baumannii* isolates were compared with imipenem resistance. There was no statistically significant relationship between resistance of isolates to colistin and resistance of isolates to imipenem (p-value=0.696). Although, there was a statistically significant relationship between resistance of isolates to tigecycline and resistance of isolates to imipenem (p-value=0.001).

As to the comparison of BMD and E test methods, for determining the resistance of *A. baumannii* strains to colistin, the difference between the methods was not significant (p-value=0.500). In contrast, the determination of *A. baumannii*'s sensitivity to tigecycline, the difference between BMD and E test methods was found to be statistically significant (p-value=0.000).

Discussion

In recent years, *A. baumannii* has exhibited high resistance to some antibiotics, causing infections that are difficult to treat, especially in hospitalized patients. *A. baumannii* causes severe nosocomial infections, such as; ventilator-associated pneumonia, urinary tract infections, endocarditis, sepsis and meningitis, particularly in immunocompromised patients.

It has been reported to increase the rates of resistant strains over the years, due to the intense and uncontrolled use of antimicrobial agents against *A. baumannii*, which has the property of being able to survive in a hospital environment. This resistance confines treatment options considerably.

Hence, the clinical importance of detecting antibiotic resistance profiles has increased, due to the fact that bacteria develops resistance to many antibiotics, including carbapenems in a short time.¹³ Resistance rates may vary regionally according to the antibiotics administered.

The distribution rates of *A. baumannii* strains, according to the clinics, have been examined in some regions of the world. For example; in a study by Odewale et al.¹⁴, *A. baumannii* strains were most frequently isolated from intensive care units (72.7%), surgical clinics (18.2%) and pediatrics (9.1%). Sivaranjani et al.¹⁵ demonstrated *A. baumannii* strains were most frequently isolated from intensive care units (36.0%), general surgical (25.0%) and Obstetrics and Gynaecology (18.0%). Biglari et al.¹⁶ isolated 38.6% of *A. baumannii* strains from intensive care units, 18.9% from surgical, and 15.1% from orthopedics and traumatology. World data has therefore exhibited that *A. baumannii* strains have been isolated from many different clinics and clinical samples.

In our study, 70.4% of the strains were isolated from the intensive care units, with 29.6% being isolated from the samples sent from other clinics. Thus, these

strains were most frequently isolated from chest diseases within the intensive care unit, anesthesia intensive care units and neonatal intensive care units, respectively. In addition, these strains were mainly isolated from neuro-surgery, orthopedics and traumatology and chest disease clinics, respectively (Table 1). Of the 110 colistin-resistant *A. baumannii* strains, 87 were isolated from intensive care units, with 23 isolated from other units. Of the 417 tigecycline-resistant *A. baumannii* strains, 278 were isolated from intensive care units, and 139 from other units. The results of our study have shown, once again, that *A. baumannii* is often isolated from intensive care units. This can be explained by the follow-up of critical patients in intensive care units, and by the more frequent use of invasive interventions, such as mechanical ventilation, tracheostomy, intubation, central catheterization and urinary catheters.

Isolated clinical samples that were carbapenem resistant *A. baumannii* have been determined in various studies. Biglari et al.¹⁶ mentioned that: *A. baumannii* strains were mostly isolated from wounds (43.3%), tracheal aspirate (31.2%), urine (8.5%), blood (5.7%) and sterile body fluids (2.8%). Ferdous et al.¹⁷ reported that: *A. baumannii* strains was determined in blood (67.7%), urine (12.9%), tracheal aspirate (8.9%) and wounds (3.3%). In our study, *A. baumannii* was isolated from tracheal aspirate (32.1%), sputum (24.5%), blood (19.4%), wounds (8.7%) and urine (7.3%) (Figure 1). In particular, it makes one think that mechanical ventilation, nasogastric catheters and tracheostomy applied in intensive care units are risk factors for *A. baumannii*, which are mostly isolated from tracheal aspirate and sputum.

Colistin and tigecycline have been proven to be effective against *A. baumannii* infections, and have been used more frequently in recent years. However, isolates that are resistant to these two antibiotics have also started to be reported.¹⁸ In our study, the rates of colistin and

tigecycline-resistant strains were determined using VITEK 2, E test and BMD methods as: 3.0%, 5.7%, 9.0% and 21.7%, 24.5%, 33%, respectively. In our study, it was found that the E test results, VITEK 2 and Broth micro-dilution results was quite different from each other (Table 2).

The resistance rates of carbapenem resistant isolates to these two antibiotics were examined in a lot of regions around the world. Henwood et al.¹⁹ reported that both colistin and tigecycline resistance were determined in 11 of 13 imipenem-resistant isolates.

Abdulzara et al.²⁰ demonstrated that colistin resistance was associated with a high level of resistance to other antimicrobials.

In our study, it was determined that the rate of colistin-resistance of carbapenem-resistant isolates was lower. However, 95.3% and 96.1% of *A. baumannii* strains were found to be resistant to imipenem and meropenem, respectively. Thus, all colistin resistant (110) and tigecycline resistant (417) strains were found to be imipenem resistant (Figure 2). This study found a statistically significant relationship between resistance of isolates to tigecycline and resistance to imipenem. In the light of this information, according to the data, we believe that carbapenem-resistant *A. baumannii* strains tend mostly to develop resistance to colistin and tigecycline.

Elabd et al.²¹ pronounced that: 4.6% of *A. baumannii* strains were found to be resistant to colistin, by using the automated system and E test method. According to the results of Rossi et al.²², which reported that 1.4% of *A. baumannii* strains were found to be resistant to colistin, by using VITEK 2 and E Test methods; whilst, Asif et al.²³ mentioned that 0.8% of *A. baumannii* strains were found to be resistant to colistin, by using the E test method.

The resistance rates of carbapenem-resistant *Acinetobacter* strains to tigecycline are higher than colistin resistance rates. However, tigecycline is still also an active drug against all *A. baumannii*, including strains

that are resistant to imipenem, and various studies have been conducted in regards to this.²⁴ In the study performed by Alhaddad et al.²⁵ the tigecycline resistance of *A. baumannii* tested by the VITEK 2 method, the resistance was determined as 12.5%. Our rates of colistin and tigecycline resistant strains, obtained by VITEK 2, were consistent with the rates of colistin and tigecycline-resistant strains rates in the world. In many studies, using the BMD method, the rates of colistin and tigecycline-resistant strains were significantly higher than the rates obtained by VITEK 2 and E test methods. In addition, VITEK 2 has several limitations in terms of the reliability of the results. VITEK 2 tigecycline results require confirmation by BMD or E test, for multi drug-resistant pathogens.²⁶ The performance of VITEK 2 and E test is also poor for colistin susceptibility testing. Thus, colistin resistant isolates should be confirmed by reference to the BMD method.²⁷ From a study conducted in Spain, 20 (19.1%) out of 115 *A. baumannii* strains were resistant to colistin and the remaining 93 (80.9%) strains were susceptible, by the BMD reference method.²⁸

In the study of Deng et al.²⁹, tigecycline resistance of *A. baumannii* was tested by BMD, and this resistance was determined as 86.0%. A study conducted by Casal et al, revealed 20 (20.0%) out of 100 *A. baumannii* strains were resistant to tigecycline, 60 (60.0%) strains were intermediate and the remaining 20 (10.0%) strains were susceptible, by the BMD reference method.³⁰ Furthermore, a study conducted in Greece, referenced 18 (90.0%) out of 20 *A. baumannii* strains were resistant to colistin, and the remaining 2 (10.0%) strains were susceptible, by the BMD reference method. In same study, it was found that all *A. baumannii* strains were resistant to tigecycline by the VITEK 2.³¹ As can be seen from the results of these studies, and our study, VITEK 2 results and BMD results differ significantly.

Conclusion

According to our results along with world data, the high rates of colistin and tigecycline resistance of *A. baumannii* isolates, isolated in intensive care units, showed that infection control measures in hospitals and antibiotic usage policies in intensive care units should be revised.

However, the susceptibility of empirically initiated antibiotics; such as colistin and tigecycline, in cases suspect of infection should be evaluated in-vitro conditions by the BMD method. Additionally, it is necessary to renew the culture and antibiogram requests by considering that resistance may develop even during treatment.

Acknowledgement

I would like to thank all the staff of the Department of Medical Microbiology, Afyonkarahisar Health Sciences University for their contributions.

Funding sources

None.

Conflict of interest

The authors declare no conflicts of interest.

References

1. Atik TK, Atik B, Kiliç O, Bektöre B, Duran H, Selek BM, et al. Epidemiological evaluation of an *Acinetobacter baumannii* outbreak observed at an intensive care unit. Saudi Med J 2018;39:767–72.
2. Grandesso S, Sapino B, Amici G, Mazzucato S, Solinas M, Gion M. Are E-test and Vitek 2 good choices for tigecycline susceptibility testing when comparing BMD for MDR and XDR *Acinetobacter baumannii*? New Microbiol 2014;37:503–8.
3. Zhao SY, Jiang DY, Xu PC, Zhang YK, Shi HF, Cao HL, et al. An investigation of drug-resistant *Acinetobacter baumannii* infections in a comprehensive hospital of East China. Annals of clinical microbiology and antimicrobials 2015;14:7.
4. Turk HD, Kus H, Arslan U, Tuncer I. In vitro synergistic activity

- of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem resistant *Acinetobacter baumannii* isolates. Bull Microbiol 2014;48:311–5.
5. Goic Barisic I, Tonkic M. The review of carbapenem resistance in clinical isolates of *Acinetobacter baumannii*. Acta Med Croatica 2009;63:285–96.
 6. Eser OK, Ergin A, Tunçkanat F, Hasçelik G. In vitro activity of tigecycline as a therapeutic option against multidrug-resistant *Acinetobacter spp.* New Microbiol 2008;31:535–42.
 7. Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ. Comparative in vitro activity of tigecycline and other antimicrobials against gram-negative and gram-positive organisms collected from the Asia-Pacific Rim as part of the tigecycline evaluation and surveillance trial (TEST). Int J Antimicrob Agents 2009;33:130–6.
 8. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005;25:11–25.
 9. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram negative bacterial infections. Lancet Infect Dis 2006;6:589–601.
 10. Falagas ME, Karageorgopoulos DE. Pan-drug resistance (PDR), extensive-drug resistance (XDR), and multi-drug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008;46:1121–2.
 11. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters [homepage on the Internet]. Växjö: EUCAST; 2015 [cited 2019 May 9]. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf
 12. United States Food and Drug Administration. Breakpoint tables for interpretation of MICs and zone diameter [homepage on the Internet]. Silver Spring: USFDA; 2017 [cited 2019 May 9]. Available from: <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm587585m>
 13. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538–82.
 14. Odewale G, Adefoye OJ, Ojo J, Adewumi FA, Olowe OA. Multidrug resistance of *Acinetobacter baumannii* in Ladoko Akintola University Teaching Hospital, Osogbo, Nigeria. Eur J Microbiol Immunol 2016;6:238–43.
 15. Sivaranjani V, Umadevi S, Srirangaraj S, Kali A, Seetha KS. Multi-drug resistant *Acinetobacter* species from various clinical samples in a tertiary care hospital from South India. Australas Med J 2013;6:697–700.
 16. Biglari S, Hanafiah A, Ramli R, Rahman MM, Khaithir TMN. Clinico-epidemiological nature and antibiotic susceptibility profile of *Acinetobacter* species. Pak J Med Sci 2013;29:469.
 17. Ferdous J, Murshed M, Shahnaz S, Duza SS, Siddique PR. Isolation of *Acinetobacter* species and their antimicrobial resistance pattern in a tertiary care hospital in Dhaka, Bangladesh. Bangladesh J Med Microbiol 2016;10:18–21.
 18. Kwon SH, Ahn HL, Han OY, La HO. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant *Acinetobacter baumannii*. Biol Pharm Bull 2014;37:340–6.
 19. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical isolates of *Acinetobacter* in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002;49:479–87.
 20. Abdulzahra AT, Khalil MAF, Elkhatib WF. First report of colistin resistance among carbapenem resistant *Acinetobacter baumannii* isolates recovered from hospitalized patients in Egypt. New Microbes New Infect 2018;26:53–8.
 21. Elabd FM, Mohamed SZ, AlAyed MSZ, Asaad AM, Alsareii SA, Qureshi MA, et al. Molecular characterization of oxacillinases among carbapenem resistant *Acinetobacter baumannii* nosocomial isolates in a Saudi hospital. J Infect Public Health 2015;8:242–7.
 22. Rossi F, Girardello R, Cury AP, DiGioia TS, Almeida JN, Duarte AJ. Emergence of colistin resistance in the largest university hospital complex of Sao Paulo, Brazil, over five years. Braz J Infect Dis 2017;21:98–101.
 23. Asif A, Cheema KH, Ashraf Z, Malik M, Imran F. Colistin resistance among gram-negative non fermentors isolated from patients at a tertiary care referral burn center. Pak J Pathol 2018;29:4–7.
 24. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new

- glycylcycline antimicrobial. *Antimicrob Agents Chemother* 2006; 50:3479–84.
25. Alhaddad MS, AlBarjas AK, Alhammar LE, AlRashed AS, Badger Emeka LI. Molecular characterization and antibiotic susceptibility pattern of *Acinetobacter baumannii* isolated in intensive care unit patients in Al-Hassa, Kingdom of Saudi Arabia. *Int J Appl Basic Med Res* 2018;8:19–23.
26. Zarkotou O, Pournaras S, Altouvas G, Pitiriga V, Tziraki M, Mamali V, et al. Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin and carbapenem-resistant gram-negative pathogens. *J Clin Microbiol* 2012;50:3747–50.
27. Bakthavatchalam YD, Veeraraghavan B, Shankar A, Thukaram B, Krishnan DN. Evaluation of colistin and polymyxin B susceptibility testing methods in *Klebsiella pneumoniae* and *Acinetobacter baumannii*. *J Infect Dev Ctries* 2018;12:504–7.
28. Arroyo LA, Curiel AG, Ibanez MEB, Llanos AC, Ruiz M, Pachon J, et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of *Acinetobacter baumannii*. *J Clin Microbiol* 2005;43:903–5.
29. Deng M, Zhu MH, Li JJ, Bi S, Sheng ZK, Hu FS, et al. Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of *Acinetobacter baumannii* from a Chinese University Hospital. *Antimicrob Agents Chemother* 2014;58:297–13.
30. Casal M, Rodríguez F, Johnson B, Garduno E, Tubau F, Lejarazu OR, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible *Acinetobacter spp.* *J Antimicrob Chemother* 2009; 64:69–72.
31. Dafopoulou K, Zarkotou O, Dimitroulia E, Hadjichristodoulou C, Gennimata V, Pournaras S, Tsakris A. Comparative evaluation of colistin susceptibility testing methods among carbapenem-nonsusceptible *Klebsiella pneumoniae* and *Acinetobacter baumannii* clinical isolates. *Antimicrob Agents Chemother* 2015; 59:4625–30.